All News

ra.hands2_.JPG

Targeting GM-CSF Works in Rheumatoid Arthritis

d RheumNow

Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Take it Back Jack! (4.26.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
AI.think_.brain_.jpg

Naproxen has no Effect on Alzheimer's

d Jack Cush, MD

A randomized controlled trial shows that chronic low-dose naproxen does not reduce progression of presymptomatic Alzheimer disease (AD).

Read Article
op.questions.jpg

More Studies Needed to Optimize the Use of Osteoporosis Drugs

d Jack Cush, MD

The Annals of Internal Medicine reports a metanalysis done to examine the optimal length of long-term osteoporosis drug treatment (ODT) and whether harms are associated with long-term ODT and while the ODT benefits are clear, the risk of rare harms and need for drug holidays is less certain.&nbsp

Read Article
PSORIASIS.LH_.jpg

Skyrizi (risankizumab) FDA Approved for Psoriasis

d Jack Cush, MD

AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis. 

Read Article
Behcets_disease.jpg

Ustekinumab Effective in Behcet's Disease

d Jack Cush, MD

A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).

Read Article
OP.density.jpg

NIH Workshop on Unmet Needs in Osteoporosis

d Jack Cush, MD

In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"

Read Article
Lupus.right_.jpg

Improved Survival in Lupus

d Jack Cush, MD

A longitudinal study of systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic has shown that mortality has decreased over time.

Read Article
Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis https://t.co/kuX8X6l99V https://t.co/p4kr42piYy

Links:

The Journal of Rheumatology jrheum ( View Tweet)
Another Step beyond the DEAs Take Back program that ocurrs twice a year (April and October), including Saturday April 27th - see my earlier tweet on this today https://t.co/WPt6VIboMW

Links:

Dr. John Cush RheumNow ( View Tweet)

Results from Nationwide Inpatient Sample Database (2003–11) finds 31,439 obstetric hosp. in RA women who had a higher maternal age (30.5 yrs) & significantly more HTN, premature membr. rupture, antepartum hemorrhage, preterm delivery, IUGR & C sections https://t.co/pz5uQH5rrx

Links:

Dr. John Cush RheumNow ( View Tweet)

Swedish population study compared 8109 RA pts and 11562 full siblings to the general population, finding the risk of acute coronary syndrome to be increased in RA (HR 1.46; 1.28 -1.67) and RA Sibs (HR 1.22; 1.09 - 1.38) w/ risks confined to seropositives https://t.co/oYUP3jgY60

Links:

Dr. John Cush RheumNow ( View Tweet)

This Saturday is National Prescription Drug Take-Back Day where you can dispose of old, unused, unwanted (Potentially harmful) prescription medicines. These are run by your local police or DPS. Use this link to find out where in your town https://t.co/eae3l6OtqC

Links:

Dr. John Cush RheumNow ( View Tweet)

Danish study of 92 355 adults compared Fx rates between new users of denosumab (DEN) or alendronate - finds no advantage for DEN for hip Fx (aHR 1.08; 0.92-1.28) or any Fx (aHR 0.92; 0.83-1.02). Data doesnt support preference for DEN in high risk pts. https://t.co/dpyRF9VxH6

Links:

Dr. John Cush RheumNow ( View Tweet)

3002 UK study shows that statin (atorvastatin) use in RA is safe and effective - resulting in significant reduction in Cardiac/MACE events (HR 0.60), LDL (HR 0.77) and CRP and confers a risk reduction similar to that seen in other populations https://t.co/Zl2KaK12P5

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis shows NSAIDS increase rates of delayed union or nonunion (OR 2.07; 1.19 to 3.61) in adults with fracture, osteotomy, fusion surgery; but not in pediatrics (OR 0.58) or with low dose/short duration NSAID exposure (OR 1.68). https://t.co/0tM8OFLhzt

Links:

Dr. John Cush RheumNow ( View Tweet)

UK NHS study shows RA patients have a 1 in 5 lifetime risk of knee and hip replacement. 13 961 RA pts fins a 22% (TKR) and 17% (THR) risk following a RA Dx (for an avg 64 yr F, nonsmoker, BMI27). Risk is even higher in younger patients. https://t.co/asOVrRUZLx

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you use PJP prophylaxis w/ Bactrim in RA pts? 2640 RA pts found only 19 cases of pneumocystis pneumonia. Risk factors were high dose MTX (OR 4.5), >65 yrs (OR 3.7), ≥2 ISPs (3.7), prednisolone ≥5 (OR 12.4) - a combo of these has a 2.3-5.8% riskof PJP. https://t.co/5Pf2FskE30

Links:

Dr. John Cush RheumNow ( View Tweet)

Should you check hydroxychloroquine levels in your #SLE patients? I do not but probably should in patients who are not in remission as nonadherence to HCQ may be as high as 50%. This is routinely available. https://t.co/UkxjMh3lQz

Links:

Dr. John Cush RheumNow ( View Tweet)

What is your best therapy when treating calcinosis cutis? (or write in your Rx)

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×